Table 1.
Baseline participant characteristics and comparison by randomization
| Overall Sample (n = 22) | Randomization 1 (n = 11) | Randomization 2 (n = 11) | p | |
|---|---|---|---|---|
| Age (in years), M (SD) | 37.59(11.91) | 38.55(11.41) | 36.63(12.86) | 0.717 |
| Sex, n (%) | 11(50%) | 5(45.5%) | 6(54.5%) | 0.670 |
| Smoking status, n (%) | 13(59.1%) | 4(36.4%) | 9(81.8%) | 0.080† |
| Anxiety Disorder, n (%) | 7(31.8%) | 0(0.0%) | 7(63.6%) | 0.004* |
| BD sub-type, n (%) I | 12(54.5%) | 6(54.5%) | 6(54.5%) | 1.000 |
| YMRS, M (SD) | 4.00(3.98) | 2.91(3.33) | 5.09(4.41) | 0.206 |
| MADRS, M (SD) | 8.27(7.86) | 5.36(4.43) | 11.18(9.56) | 0.082† |
| Cannabis Withdrawal Scale, M (SD) | 36.73(32.99) | 36.45(37.37) | 37.00(29.81) | 0.970 |
| Marijuana Craving Quest., M (SD) | 37.41(17.07) | 36.18(15.38) | 38.64(19.29) | 0.745 |
| Cannabis use (grams/day), M (SD) | 3.00(3.41) | 1.47(2.32) | 4.52(3.72) | 0.032* |
| Medication (%) | ||||
| Lithium | 4(18.2%) | 2(18.2%) | 2(18.2%) | 1.000 |
| Antipsychotic | 18(81.8%) | 8(72.7%) | 10(90.9%) | 0.586 |
| Anticonvulsant | 9(40.9%) | 4(36.4%) | 5(45.5%) | 1.000 |
| Antidepressant | 9(40.9%) | 4(36.4%) | 5(45.5%) | 1.000 |
χ2 (categorical variables) tests, using Fisher’s Exact when applicable, and independent samples t-tests (continuous variables) were performed.
BD = bipolar disorder; YMRS, Young Mania Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; Quest. = Questionnaire.
†
p < 0.10;
*
p < 0.05.